HR Execs on the Move


 
NYMOZARFEX (TM) is given in an in-office procedure that is administered in a few minutes without need of anesthesia or analgesia. The drug has been tested in clinical trials involving overall more than 1750 patients with over 1600 injections administered including over 1200 Fexapotide administrations. Fexapotide has led to significant long-term improvements and has shown an excellent safety profile without the side effects normally associated with existing BPH treatments.
  • Number of Employees: 100-250
  • Annual Revenue: $10-50 Million
  • www.nymox.com
  • Heights Plaza 777 Terrace Avenue
    Hasbrouck Heights, NJ USA 07604
  • Phone: 800.936.9669

Executives

Name Title Contact Details

Similar Companies

Microfil

Microfil LLC is a Bridgman, MI-based company in the Healthcare, Pharmaceuticals, & Biotech sector.

Murphy Medical Center

Murphy Medical Center is one of the leading companies in Healthcare, Pharmaceuticals, & Biotech industry. Murphy Medical Center is based in Murphy, NC. You can find more information on Murphy Medical Center at www.murphymedical.org

De Kroyft-Metz

De Kroyft-Metz is a Peoria, IL-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Health Sphere Wellness Center

Health Sphere Wellness Center is a Brentwood, TN-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Nivalis Therapeutics

Nivalis Therapeutics (formerly N30Pharma) is developing a novel class of disease modifying therapies that preserve intracellular GSNO (S-nitrosoglutathione), a key regulator of organ repair, regeneration, and healing. The Company’s lead program is focused on cystic fibrosis. As the body’s primary reservoir of nitric oxide (NO), GSNO plays a pivotal role in NO signaling. Decreased GSNO levels are associated with inflammatory lung disease, and with increased activity of GSNOR (GSNO reductase), the primary catabolizing enzyme of GSNO. Nivalis Therapeutics has developed a broad portfolio of proprietary, potent, small molecule inhibitors of GSNOR that have been shown to preserve endogenous GSNO levels and to be effective in “gold-standard” models of inflammatory lung disease. Nivalis Therapeutics is located in Boulder, Colorado.